Kintara Posts VAL-083 Data As Adjuvant Therapy In Newly-Diagnosed GBM Patients
Kintara Therapeutics Inc (NASDAQ:KTRA) announced topline data results from the newly diagnosed adjuvant arm of its Phase 2 clinical study. The…
Kintara Therapeutics Reports Topline Results From Phase 2 Study Of VAL-083 As Adjuvant Therapy For Newly-Diagnosed Glioblastoma Multiforme Patients
Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to, current
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Delcath Systems (NASDAQ:DCTH) stock increased by 8.87% to $11.9 during Friday's after-market session. This security traded at a volume of 379 shares come close, making up 0.45% of its average volume over the last 100 days. The company's market cap stands at $87.4 million.
Kintara Therapeutics Shares See Volume; Zacks SCR Issues Report On Co’s Phase 2 Topline Results
https://scr.zacks.com/news/news-details/2021/KTRA-Phase-II-Topline-article/default.aspx
56 Biggest Movers From Friday
Gainers
Sequential Brands Group, Inc. (NASDAQ: SQBG) jumped 89.2% to settle at $15.70.